Startup Microlin Bio last week revealed that it is aiming to price shares in its planned initial public offering at between $6 and $8 apiece.
The company did not provide any details regarding the expected timing of the transaction.
As reported by Gene Silencing News, Microlin filed to go public in January, just months after it was founded. The company's focus is the development of microRNA drugs and diagnostics based on intellectual property exclusively licensed from Ohio State University.